Stock Track | BeOne Medicines (ONC) Soars 5.07% on Strong Q3 Earnings, Raised Guidance

Stock Track11-07

Shares of BeOne Medicines (ONC) are soaring 5.07% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report and raised full-year guidance. The biotechnology firm, also known as BEIGENE, has demonstrated robust growth across its product portfolio, particularly with its flagship drug BRUKINSA.

BeOne Medicines reported adjusted earnings of $1.09 per share for the quarter ended September 30, significantly beating the analysts' consensus estimate of 78 cents per share. Revenue surged 41% year-over-year to $1.41 billion, surpassing the expected $1.36 billion. The strong performance was primarily driven by BRUKINSA's global sales, which reached RMB 7.423 billion in Q3, a 51.0% increase from the previous year.

Buoyed by these results, BeOne Medicines raised its full-year 2025 revenue guidance to RMB 36.2–38.1 billion, up from the previous forecast of RMB 35.8–38.1 billion. This optimistic outlook is supported by BRUKINSA's leading position in the U.S. market and its continued expansion in Europe and other key regions. Additionally, the company's pipeline is progressing well, with 20 critical milestones expected within the next 18 months, including advancements in hematology, solid tumors, and immunology treatments. This robust pipeline and strong financial performance have reinforced investor confidence in BeOne Medicines' growth trajectory, contributing to today's stock surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195321696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 00:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195321696","market":"hk","top_or_hot":-1,"title":"Stock Track | BeOne Medicines (ONC) Soars 5.07% on Strong Q3 Earnings, Raised Guidance","media":"Stock Track","content":"<p>Shares of BeOne Medicines (ONC) are soaring 5.07% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report and raised full-year guidance. The biotechnology firm, also known as BEIGENE, has demonstrated robust growth across its product portfolio, particularly with its flagship drug BRUKINSA.</p>\n\n<p>BeOne Medicines reported adjusted earnings of $1.09 per share for the quarter ended September 30, significantly beating the analysts' consensus estimate of 78 cents per share. Revenue surged 41% year-over-year to $1.41 billion, surpassing the expected $1.36 billion. The strong performance was primarily driven by BRUKINSA's global sales, which reached RMB 7.423 billion in Q3, a 51.0% increase from the previous year.</p>\n\n<p>Buoyed by these results, BeOne Medicines raised its full-year 2025 revenue guidance to RMB 36.2–38.1 billion, up from the previous forecast of RMB 35.8–38.1 billion. This optimistic outlook is supported by BRUKINSA's leading position in the U.S. market and its continued expansion in Europe and other key regions. Additionally, the company's pipeline is progressing well, with 20 critical milestones expected within the next 18 months, including advancements in hematology, solid tumors, and immunology treatments. This robust pipeline and strong financial performance have reinforced investor confidence in BeOne Medicines' growth trajectory, contributing to today's stock surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeOne Medicines (ONC) Soars 5.07% on Strong Q3 Earnings, Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeOne Medicines (ONC) Soars 5.07% on Strong Q3 Earnings, Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 00:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of BeOne Medicines (ONC) are soaring 5.07% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report and raised full-year guidance. The biotechnology firm, also known as BEIGENE, has demonstrated robust growth across its product portfolio, particularly with its flagship drug BRUKINSA.</p>\n\n<p>BeOne Medicines reported adjusted earnings of $1.09 per share for the quarter ended September 30, significantly beating the analysts' consensus estimate of 78 cents per share. Revenue surged 41% year-over-year to $1.41 billion, surpassing the expected $1.36 billion. The strong performance was primarily driven by BRUKINSA's global sales, which reached RMB 7.423 billion in Q3, a 51.0% increase from the previous year.</p>\n\n<p>Buoyed by these results, BeOne Medicines raised its full-year 2025 revenue guidance to RMB 36.2–38.1 billion, up from the previous forecast of RMB 35.8–38.1 billion. This optimistic outlook is supported by BRUKINSA's leading position in the U.S. market and its continued expansion in Europe and other key regions. Additionally, the company's pipeline is progressing well, with 20 critical milestones expected within the next 18 months, including advancements in hematology, solid tumors, and immunology treatments. This robust pipeline and strong financial performance have reinforced investor confidence in BeOne Medicines' growth trajectory, contributing to today's stock surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONC","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1195321696","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195321696","pubTimestamp":1762445047,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of BeOne Medicines (ONC) are soaring 5.07% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report and raised full-year guidance. The biotechnology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONC":"百济神州"},"translate_title":"股票追踪|BeOne Medicines(ONC)第三季度盈利强劲，指引上调，股价飙升5.07%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1},"content_text":"Shares of BeOne Medicines (ONC) are soaring 5.07% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report and raised full-year guidance. The biotechnology firm, also known as BEIGENE, has demonstrated robust growth across its product portfolio, particularly with its flagship drug BRUKINSA.\nBeOne Medicines reported adjusted earnings of $1.09 per share for the quarter ended September 30, significantly beating the analysts' consensus estimate of 78 cents per share. Revenue surged 41% year-over-year to $1.41 billion, surpassing the expected $1.36 billion. The strong performance was primarily driven by BRUKINSA's global sales, which reached RMB 7.423 billion in Q3, a 51.0% increase from the previous year.\nBuoyed by these results, BeOne Medicines raised its full-year 2025 revenue guidance to RMB 36.2–38.1 billion, up from the previous forecast of RMB 35.8–38.1 billion. This optimistic outlook is supported by BRUKINSA's leading position in the U.S. market and its continued expansion in Europe and other key regions. Additionally, the company's pipeline is progressing well, with 20 critical milestones expected within the next 18 months, including advancements in hematology, solid tumors, and immunology treatments. This robust pipeline and strong financial performance have reinforced investor confidence in BeOne Medicines' growth trajectory, contributing to today's stock surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195321696","isCrawlerRequest":true}